{
    "clinical_study": {
        "@rank": "139742", 
        "arm_group": [
            {
                "arm_group_label": "Morphine prolonged release", 
                "arm_group_type": "Active Comparator", 
                "description": "10 mg or 30 mg tablets taken orally twice daily. Dose based on participant weight. The dose must not exceed a total of 200 mg per day for participants weighing 55 kg or more."
            }, 
            {
                "arm_group_label": "Tapentadol prolonged-release", 
                "arm_group_type": "Experimental", 
                "description": "25 mg and or 100 mg tablets taken orally.  Dose based on participant weight. The dose must not exceed a total of 500 mg per day for participants weighing 55 kg or more."
            }, 
            {
                "arm_group_label": "Tapentadol after morphine", 
                "arm_group_type": "Other", 
                "description": "Participants that were randomized to morphine in part 1 of the open-label period can continue with tapentadol in part 2 of the trial. Participants will be rotated to tapentadol prolonged release with 70% of the current morphine equivalent dose or lower."
            }, 
            {
                "arm_group_label": "Tapentadol open-label extension", 
                "arm_group_type": "Other", 
                "description": "Participants that were randomized to tapentadol in part 1 of the open-label period can continue with tapentadol in part 2 of the trial. Participants will continue on the current dose and if necessary can modify their tapentadol prolonged release dosage."
            }, 
            {
                "arm_group_label": "Observation period after tapentadol in part 1", 
                "arm_group_type": "No Intervention", 
                "description": "Participants not completing Part 1 can enter the Observation Period."
            }, 
            {
                "arm_group_label": "Observation period after morphine in part 1", 
                "arm_group_type": "No Intervention", 
                "description": "Participants not completing Part 1 can enter the Observation Period."
            }
        ], 
        "brief_summary": {
            "textblock": "Tapentadol has already been studied in adults. This study is needed to find out if\n      tapentadol works and is safe to use in children and adolescents with long-term pain.\n\n      During the first 2 weeks of the study (Part 1), participants will be given either tapentadol\n      or morphine prolonged-release tablets. Assignment will be done randomly (like tossing a\n      coin). The participant and the caregiver will know which medication they are taking. The\n      primary endpoint is based on data collected in Part 1 of this trial.\n\n      If eligible and willing, participants from Part 1 can enter a 12 month follow-up  period\n      (Part 2). In Part 2 of this trial participants will be treated with tapentadol prolonged\n      release tablets or with the standard of care (observation arm)."
        }, 
        "brief_title": "A Study to Look at Tapentadol Tablets in Children and Adolescents in Pain", 
        "condition": "Pain", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Part 1 - Randomized to open-label, active comparator controlled treatment\n\n        Participants are eligible for the trial at if all the following apply:\n\n          -  Informed consent (if applicable assent) obtained.\n\n          -  Male or female participant at least 6 years of age at the Enrollment Visit and less\n             than 18 years of age on Day 14.\n\n          -  Participant has an underlying long-term pain condition that is, according to the\n             judgment of the investigator, expected to require a twice-daily prolonged release\n             opioid treatment until at least the end of the 14-day Treatment Period.\n\n          -  Participant can swallow tablets of appropriate size.\n\n          -  Participant is able to participate in the trial as planned and willing to comply with\n             the requirements of the protocol including refraining from drinking beverages\n             containing alcohol and recreational intake of drugs while on study medication.\n\n        Participants must satisfy the following criteria before allocation to treatment:\n\n          -  Less than 18 years of age.\n\n          -  No opioid intake or last calculated morphine equivalent dose of less than 3.5 mg/kg\n             per day.\n\n          -  Participant has a body weight of at least 17.5 kg.\n\n          -  If a female of childbearing potential (post menarchal and not surgically incapable of\n             childbearing) and sexually active, must practice an effective method of birth control\n             (e.g., prescription oral contraceptives, contraceptive injections, intrauterine\n             device, double barrier method, contraceptive patch) before allocation to study\n             medication until the end of intake of study medication.\n\n          -  If a female and post menarchal or older than 12 years, has a negative urine pregnancy\n             test on the day before or on the day of allocation to study medication.\n\n        Part 2\n\n        Inclusion criteria for the Tapentadol Open-label extension period:\n\n          -  Participant has completed the 14-day Treatment Period.\n\n          -  Participant is still in need of prolonged release opioid treatment.\n\n          -  Participant does not meet any of the compulsory discontinuation criteria.\n\n        Exclusion Criteria:\n\n        Participants are not eligible for the trial if any of the following apply.\n\n        The following will be checked at enrollment:\n\n          -  Has been previously enrolled in this trial or a previous trial with tapentadol.\n\n          -  Has a clinically relevant history of hypersensitivity, allergy, or contraindication\n             to morphine or tapentadol or any ingredient, including galactose intolerance (see\n             investigator's brochure for tapentadol PR and summary of product characteristics for\n             morphine PR), or naloxone.\n\n          -  History or current condition of any one of the following:\n\n               -  Seizure disorder or epilepsy.\n\n               -  Serotonin syndrome.\n\n               -  Traumatic or hypoxic brain injury, brain contusion, stroke, transient ischemic\n                  attack, intracranial hematoma, posttraumatic amnesia, brain neoplasm, or\n                  episode(s) of more than 24 hours duration of unconsciousness.\n\n          -  History or current condition of any one of the following:\n\n               -  Moderate to severe renal or hepatic impairment.\n\n               -  Abnormal pulmonary function or clinically relevant respiratory disease (e.g.,\n                  acute or severe bronchial asthma, hypercapnia)\n\n          -  History of alcohol or drug abuse in the investigator's judgment, based on history and\n             physical examination. Drugs of abuse detected in urine screen unless explained by\n             allowed concomitant medication\n\n          -  Participant has:\n\n               -  A clinically relevant abnormal electrocardiogram.\n\n               -  Signs of pre-excitation syndrome.\n\n               -  Brugada's syndrome.\n\n               -  QT or QTcF (Fridericia) interval greater than 470 ms.\n\n          -  Any surgery scheduled during the first 14 days of the trial that is expected to\n             require post-surgical intensive care unit (ICU) treatment, or that requires\n             post-surgical parenteral pain-treatment, or may, affect the safety of the\n             participant.\n\n          -  Participant is not able to understand and comply with the protocol as appropriate for\n             the age of the subject or subject is cognitively impaired in the investigator's\n             judgment such that they cannot comply with the protocol.\n\n          -  Participant, parent or the legal representative is an employee of the investigator or\n             trial site, with direct involvement in the proposed trial or other studies under the\n             direction of that investigator or trial site, or family member of the employees or\n             the investigator.\n\n        The following will be checked at the enrollment and the allocation visits:\n\n          -  Has a concomitant disease or disorder (e.g., endocrine, metabolic, neurological,\n             psychiatric, infection) that in the opinion of the investigator may affect or\n             compromise subject safety during the trial participation.\n\n          -  Pancreatic/biliary tract disease (e.g., pancreatitis) or paralytic ileus.\n\n          -  Intake of forbidden concomitant medication/use of forbidden therapies (see synopsis\n             section Concomitant medications/therapies).\n\n        The following will be checked at the allocation to treatment visit:\n\n          -  Has received a drug or used a medical device not approved for human use within 30\n             days prior to visit.\n\n          -  Based on data from the local laboratory, one or more of:\n\n               -  Total serum bilirubin greater than 2.0 mg/dL.\n\n               -  Serum albumin less than 2.8 g/dL.\n\n               -  Aspartate transaminase or alanine transaminase greater than 5 times upper limit\n                  of normal.\n\n          -  Based on data from the local laboratory, creatinine clearance less than 30 mL/min per\n             1.73 m2 (calculated according to a formula that is appropriate for the respective age\n             group).\n\n          -  If the participant suffers from non-cancer related pain: participation in any\n             interventional clinical trial within 30 days prior to visit."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "17 Years", 
            "minimum_age": "6 Years"
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 28, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02151682", 
            "org_study_id": "KF5503-66", 
            "secondary_id": [
                "2012-004360-22", 
                "U1111-1154-4572"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Tapentadol prolonged-release", 
                    "Tapentadol after morphine", 
                    "Tapentadol open-label extension"
                ], 
                "description": "Participants aged from 6 years to less than 18 years with body weight less than 22.5 kg (but more than 17.5 kg) will start on 25 mg of tapentadol orally (by mouth) twice daily during the first 24 hours and then if necessary gradually stepwise increase the dose.", 
                "intervention_name": "Tapentadol prolonged release", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Palexia\u00ae", 
                    "Nucynta\u00ae", 
                    "Yantil\u00ae"
                ]
            }, 
            {
                "arm_group_label": "Morphine prolonged release", 
                "description": "Participants aged from 6 years to less than 18 years with body weight less than 22.5 kg (but more than 17.5 kg) will start on 10 mg of morphine orally twice daily during the first 24 hours and then and then if necessary gradually stepwise increase the dose.", 
                "intervention_name": "Morphine prolonged release", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Morphine"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "chronic pain", 
            "opioid"
        ], 
        "lastchanged_date": "May 29, 2014", 
        "number_of_arms": "6", 
        "official_title": "An Open-label Trial, Enrolling Subjects Aged 6 Years to Less Than 18 Years Suffering From Pain Requiring Prolonged Release Opioid Treatment, to Evaluate the Safety and Efficacy of Tapentadol PR Versus Morphine PR, Followed by an Open-label Extension.", 
        "other_outcome": [
            {
                "description": "Pain Intensity will be assessed by scoring \"pain right now\" twice daily. \"Pain right now\" will be scored by every participant using the Visual Analog Score (VAS) as well as the Faces Pain Scale-Revised (FPS-R) at each time point in an electronic diary.\nThe pain intensity will first be documented using the VAS and directly thereafter the FPS-R. If required, pain intensity diary entry maybe assisted by the legal guardian or a health care provider.\nThe FPS-R is a self-reported 6 point scale ranging from \"no pain\" to \"very much pain\". Facial representations are used to indicate how much the pain hurts.", 
                "measure": "Change in pain intensity in the open-label, active-controlled treatment period", 
                "safety_issue": "No", 
                "time_frame": "Baseline; Day 14 (End of Part 1)"
            }, 
            {
                "description": "Pain Intensity will be assessed by scoring \"pain right now\" twice daily. \"Pain right now\" will be scored by every participant using the Visual Analog Score (VAS) as well as the Faces Pain Scale-Revised (FPS-R) at each time point.\nIn this part of the trial the pain intensity will first be documented using the VAS and directly thereafter the FPS-R. If required, pain intensity diary entry maybe assisted by the legal guardian or a health care provider.\nPain intensity on the VAS will be scored by the participant on a paper based 100 mm VAS ranging from \"no pain\" to \"pain as bad as it could be\".\nThe FPS-R is a self-reported 6 point scale ranging from \"no pain\" to \"very much pain\". Facial representations are used to indicate how much the pain hurts.", 
                "measure": "Change in pain intensity in the tapentadol open-label extension period", 
                "safety_issue": "No", 
                "time_frame": "Day 15; Day 379 (End of Part 2)"
            }, 
            {
                "description": "The number of doses of morphine oral solution used.", 
                "measure": "Use of rescue medication in the open-label, active-controlled treatment period", 
                "safety_issue": "No", 
                "time_frame": "Day 1; Day 14 (End of Part1)"
            }, 
            {
                "description": "Tapentadol concentrations will measured in participants in the tapentadol treatment arm.", 
                "measure": "Pharmacokinetic Concentrations of Tapentadol", 
                "safety_issue": "No", 
                "time_frame": "Day 1; Day 14 (End of Part1)"
            }, 
            {
                "description": "Tapentadol-O-glucuronide is a metabolite of tapentadol. Metabolites are sometimes referred to as \"breakdown products\". The body alters the administered medication to a metabolite so that can be more easily or quickly removed from the body. Tapentadol-O-glucoronide concentrations will be measured.", 
                "measure": "Pharmacokinetic Concentrations of Tapentadol-O-glucoronide", 
                "safety_issue": "No", 
                "time_frame": "Day 1; Day 14 (End of Part1)"
            }, 
            {
                "description": "Palatability will be determined by asking the participant \"How does the medication taste\". The participant will be requested to give a score on a 5 point rating scale. The response can range from really bad to really good.", 
                "measure": "Palatability of study medication", 
                "safety_issue": "No", 
                "time_frame": "Day 8"
            }, 
            {
                "description": "Palatability will be determined by asking the participant \"How does the medication taste\". The participant will be requested to give a score on a 5 point rating scale. The response can range from really bad to really good.", 
                "measure": "Palatability of study medication", 
                "safety_issue": "No", 
                "time_frame": "Day 14"
            }, 
            {
                "description": "Acceptability will be determined by asking the participant \"Swallowing the medication is...\". The participant will be requested to give a score on a 5 point rating scale. The response can range from really difficult to really easy.", 
                "measure": "Acceptability of study medication", 
                "safety_issue": "No", 
                "time_frame": "Day 8"
            }, 
            {
                "description": "Acceptability will be determined by asking the participant \"Swallowing the medication is...\". The participant will be requested to give a score on a 5 point rating scale. The response can range from really difficult to really easy.", 
                "measure": "Acceptability of study medication", 
                "safety_issue": "No", 
                "time_frame": "Day 14"
            }, 
            {
                "description": "Constipation will be assessed using the modified constipation assessment scale (CAS). This is an 8-item questionnaire where the observer will score constipation on a nominal scale (no problem, some problem or severe problem). The response to an item could also be scored as \"unable to assess\".", 
                "measure": "Constipation", 
                "safety_issue": "Yes", 
                "time_frame": "Day 15; Day 379 (End of Part 2)"
            }, 
            {
                "description": "Each participant will be requested to score 15 items on the 16 item questionnaire for 7 days after discontinuation of treatment. Opiate withdrawal symptoms will be assessed using the subjective opiate withdrawal scale (SOWS) questionnaire. The participants rate their experience on specific questions on a 0 (not at all) to 4 (extremely). The minimum score is 0, the maximum score is 64. THe SOWS is designed to reflect common motoric, autonomic, musculoskeletal and psychic signs and symptoms of opiate withdrawal.", 
                "measure": "Subjective opiate withdrawal scale", 
                "safety_issue": "Yes", 
                "time_frame": "Day 386"
            }, 
            {
                "description": "In the event that more than 10% of participants discontinue in one of the 3 study medication treatment groups a survival analysis will be performed.\nThe discontinuation from study medication due to lack of efficacy and due to treatment emergent events will be analyzed for both the tapentadol prolonged release and morphine prolonged release treatment arms in part 1 of the trial, as well as for tapentadol prolonged release treatment in part 2 of the trial.", 
                "measure": "Time to discontinuation.", 
                "safety_issue": "Yes", 
                "time_frame": "Day 1; Day 379"
            }
        ], 
        "overall_contact": {
            "email": "clinical-trials@grunenthal.com", 
            "last_name": "Gr\u00fcnenthal Trial Information Desk", 
            "phone": "+49 241 569 3223"
        }, 
        "overall_official": {
            "affiliation": "Gr\u00fcnenthal GmbH", 
            "last_name": "Director Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
                "Belgium: Federal Agency for Medicinal Products and Health Products", 
                "Spain: Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
                "Australia: Department of Health and Ageing Therapeutic Goods Administration", 
                "Austria: Austrian Medicines and Medical Devices Agency", 
                "Bulgaria: Ministry of Health", 
                "Chile: Instituto de Salud P\u00fablica de Chile", 
                "Croatia: Agency for Medicinal Product and Medical Devices", 
                "Hungary: Ministry of Health, Social and Family Affairs", 
                "Italy: The Italian Medicines Agency", 
                "Lithuania: State Medicine Control Agency - Ministry of Health", 
                "Mexico: Ministry of Health", 
                "Netherlands: Medicines Evaluation Board (MEB)", 
                "Peru: Instituto Nacional de Salud", 
                "Portugal: INFARMED, National Authority of Medicines and Health Products, IP", 
                "Slovakia: State Institute for Drug Control", 
                "Slovenia: Ministry of Health", 
                "Germany: Federal Institute for Drugs and Medical Devices", 
                "Switzerland: Swissmedic"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "October 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Responders are participants who meet both of the following criteria:\nCompletion of the 14-day Treatment Period (Part 1).\nOne of the following calculated from the scheduled pain assessments (\"pain right now\") documented during the last 3 days of the Treatment Period:\nAverage pain less than 50 on a visual analog scale (VAS) for subjects aged 12 years to less than 18 years; or less than 5 on the Faces Pain Scale-revised (FPS-R) for subjects aged 6 years to less than 12 years.\nAverage reduction from baseline of pain greater than and equal to 20 on a VAS for subjects aged 12 years to less than 18 years; or greater and equal to 2 on the FPS-R for subjects aged 6 years to less than 12 years.", 
            "measure": "Proportion of participants classified as responders", 
            "safety_issue": "No", 
            "time_frame": "up to Day 14 (End of Part 1)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02151682"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Constipation will be assessed using the modified constipation assessment scale (CAS). This is an 8-item questionnaire where the observer will score constipation on a nominal scale (no problem, some problem or severe problem). The response to an item could also be scored as \"unable to assess\".", 
                "measure": "Constipation", 
                "safety_issue": "Yes", 
                "time_frame": "Day 1; Day 14 (End of Part 1)"
            }, 
            {
                "description": "Tolerability will be assessed by the number and type of adverse events and adverse drug reactions by treatment group during the different trial periods, on a participant and event level.", 
                "measure": "Tolerability", 
                "safety_issue": "Yes", 
                "time_frame": "Day 1 (Start of Part 1); Day 379 (End of Part 2)"
            }
        ], 
        "source": "Gr\u00fcnenthal GmbH", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Gr\u00fcnenthal GmbH", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}